1988 CytRx -Products to increase blood flow and dissolve clots for heart attacks and other blood vessel issues. Technology licensed from Emory University. Gorlin invested $200,000, raised additional funds and then took it public. The first IPO was $6 million. During Gorlin’s leadership, the company reached a market cap of over $200 million. NASDAQ: CYTR  (http://www.cytrx.com)

1986 THERAGENICS -Palladium implants for prostate cancer. Founded with Dr. John Russell, director of the Frank Neely Nuclear Research Center at Georgia Tech. Initially a privately financed company. Performed a reverse merger into a public shell value of $6 million. Managed from inception through sale. Reached market value of over $1 billion during Gorlin’s involvement. NYSE: TGX  (http://www.theragenics.com)

1981 HYCOR – Monoclonal Antibodies. Founded with Dr. Paul Price and Dr. David Gordon who at the time, were co-directors of the Hybridoma Lab at the Centers for the Disease Control & Prevention (CDC). Gorlin financed company prior to $6 million IPO. Second Monoclonal company to go public. Sold to Agilent for $100 million. Currently, subsidiary of Agilent. (http://www.hycorbiomedical.com)